Patents by Inventor Zhengxiang Gu

Zhengxiang Gu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
    Publication number: 20080194625
    Abstract: The invention provides for compounds of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.
    Type: Application
    Filed: April 24, 2008
    Publication date: August 14, 2008
    Inventors: Chongqing Sun, Doree Sitkoff, William R. Ewing, Yanting Huang, Bruce A. Ellsworth, Richard B. Sulsky, Annapurna Pendri, Samuel Gerritz, Natesan Murugesan, Zhengxiang Gu
  • Azabicyclic heterocycles as cannabinoid receptor modulators
    Patent number: 7378418
    Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: May 27, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guixue Yu, William R. Ewing, Amarendra B. Mikkilineni, Annapurna Pendri, Philip M. Sher, Samuel Gerritz, Bruce A. Ellsworth, Gang Wu, Yanting Huang, Chongqing Sun, Natesan Murugesan, Zhengxiang Gu, Ying Wang, Doree Sitkoff, Stephen R. Johnson, Ximao Wu
  • Dihydropyrimidone inhibitors of calcium channel function
    Patent number: 7166603
    Abstract: Compounds having the formula, enantiomers, diastereomers, solvates and salts thereof, where R1, R2, R3, R4, A, X, and J are described herein, are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: January 23, 2007
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Natesan Murugesan, Gregory S. Bisacchi, William R. Ewing, Guixue Yu, Zhengxiang Gu, Todd Friends, Minsheng Zhang
  • Substituted dihydropyrimidine inhibitors of calcium channel function
    Patent number: 7157461
    Abstract: The present invention relates to substituted dihydropyrimidine inhibitors of calcium channel function having formula I where A, a, J, R1, R2 R3, R4, and R5, are defined herein; pharmaceutical compositions comprising said compounds; and methods of treating calcium channel-dependent disorders, including hypertension.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: January 2, 2007
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Natesan Murugesan, Gergory S. Bisacchi, William R. Ewing, Zhengxiang Gu
  • Triazolopyrimidine cannabinoid receptor 1 antagonists
    Publication number: 20060287341
    Abstract: The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.
    Type: Application
    Filed: June 16, 2006
    Publication date: December 21, 2006
    Inventors: Gang Wu, Amarendra Mikkilineni, Philip Sher, Natesan Murugesan, Zhengxiang Gu
  • Inhibitors of 15-lipoxygenase
    Publication number: 20060063823
    Abstract: The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
    Type: Application
    Filed: September 21, 2005
    Publication date: March 23, 2006
    Inventors: Natesan Murugesan, John Macor, Zhengxiang Gu, Leena Fadnis
  • Azabicyclic heterocycles as cannabinoid receptor modulators
    Publication number: 20050143381
    Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
    Type: Application
    Filed: December 17, 2004
    Publication date: June 30, 2005
    Inventors: Guixue Yu, William Ewing, Amarendra Mikkilineni, Annapurna Pendri, Philip Sher, Samuel Gerritz, Bruce Ellsworth, Gang Wu, Yanting Huang, Chongqing Sun, Natesan Murugesan, Zhengxiang Gu, Ying Wang, Doree Sitkoff, Stephen Johnson, Ximao Wu
  • Substituted dihydropyrimidine inhibitors of calcium channel function
    Publication number: 20050043322
    Abstract: The present invention relates to substituted dihydropyrimidine inhibitors of calcium channel function having formula I where A, a, J, R1, R2 R3, R4, and R5, are defined herein; pharmaceutical compositions comprising said compounds; and methods of treating calcium channel-dependent disorders, including hypertension.
    Type: Application
    Filed: July 23, 2004
    Publication date: February 24, 2005
    Inventors: Natesan Murugesan, Gergory Bisacchi, William Ewing, Zhengxiang Gu
  • Dihydropyrimidone inhibitors of calcium channel function
    Publication number: 20050043339
    Abstract: Compounds having the formula, enantiomers, diastereomers, solvates and salts thereof, where R1, R2, R3, R4, A, X, and J are described herein, are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.
    Type: Application
    Filed: July 22, 2004
    Publication date: February 24, 2005
    Inventors: Natesan Murugesan, Gregory Bisacchi, William Ewing, Guixue Yu, Zhengxiang Gu, Todd Friends, Minsheng Zhang
  • Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
    Patent number: 6852745
    Abstract: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: February 8, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Natesan Murugesan, John E. Tellew, John E. Macor, Zhengxiang Gu
  • Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
    Patent number: 6835741
    Abstract: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: December 28, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Natesan Murugesan, John E. Tellew, John E. Macor, Zhengxiang Gu
  • Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
    Publication number: 20040127515
    Abstract: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 26, 2003
    Publication date: July 1, 2004
    Inventors: Natesan Murugesan, John E. Tellew, John E. Macor, Zhengxiang Gu
  • Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
    Publication number: 20040106833
    Abstract: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 26, 2003
    Publication date: June 3, 2004
    Inventors: Natesan Murug San, John E. Tellew, John E. Macor, Zhengxiang Gu
  • Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
    Patent number: 6638937
    Abstract: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: October 28, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Natesan Murugesan, John E. Tellew, John E. Macor, Zhengxiang Gu
  • Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
    Publication number: 20020143024
    Abstract: Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 14, 2000
    Publication date: October 3, 2002
    Inventors: Natesan Murugesan, John E. Tellew, Jhon E. Macor, Zhengxiang Gu
  • Isoxazolyl endothelin antagonists
    Patent number: 6043265
    Abstract: The compounds N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-bi phenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methy l]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide, and salts thereof, useful as endothelin antagonists.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: March 28, 2000
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Natesan Murugesan, Joel C. Barrish, Zhengxiang Gu, Richard A. Morrison